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Plasmodium vivax, the agent of one of the tertian malarias, is widespread in
Asia, Central and South America, and less frequent in Africa . Although infection
with this parasite is rarely fatal, the course of the disease is characterized by
frequent relapses, slow development of acquired immunity and the presence of
dormant forms of the parasite in the liver, which can persist for several years (1) .
Protective immunity against rodent, monkey (2), and human malaria (including
P . vivax) (3) has been achieved by vaccination with gamma-irradiated sporozoites,
the infective stage of parasite found in the salivary gland of the Anopheles
mosquito vector. The antigen involved in protective immunity to sporozoites is
the circumsporozoite (CS)' protein, a stage-specific membrane molecule with
unusual structural and immunological properties (4). It contains a large central
domain, occupying close to half of the polypeptide chain, formed by tandem
repeats of 4-12 amino acids whose composition varies in different species (and
sometimes strains) of malaria parasites (5) . Most of the antibodies found in the
serum of humans (6, 7) or of experimental animals inoculated with sporozoites,
and all mAbs so far raised against this stage of the parasite, are directed against
repetitive epitopes in this domain . Monovalent Fab fragments of mAbs against
the repetitive epitopes neutralize parasite infectivity in vitro and in vivo in several
experimental models of malaria (8, 9) . Epidemiological evidence shows that
acquired immunity and resistance to malaria infection in humans is age depend-
ent and associated with the development of high levels of antibodies against the
repeats (10, 11) .
The P. vivax CS protein gene has been recently cloned and sequenced (12,
13) . It encodes a protein of 373 amino acids with general features resembling
those of other members of the family (4, 5, 14) . Here we report the results of
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FIGURE 1 .
￿
(a) Schematic representation of theCS protein gene and of thesegment expressed
in yeast. The assigned amino acid numberscorrespond to those of Arnot et al . (12). In addition
to signal and presumed anchor sequences, and areas containing large numbers of charged
amino acids, a large portion of the CS molecule consists of tandem repeats of nine amino
acids. As shown, repeats bearing alanine in the fourth position (") predominate at one end of
the repeat domain . (b) Plasmid constructions for the expression ofP . vivaxCS proteins in yeast
as explained in the Materials and Methods section .
our effort to develop a recombinant DNA-derived vaccine against P . vivax
consisting of portions of the CS polypeptide with potential immunoprophylactic
value, including the repeat domain .
Materials and Methods
Plasmid Construction and Yeast Expression .
￿
A Fok-1/Ban-1 fragment encoding amino
acidsAla 77 toThr 306 of theP . vivax CS gene (Fig . 1 a) wasexcised frompUC9 plasmids1162
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containing this region of DNA. Synthetic adapters containing in-frame initiation and
termination codons (as shown in Fig. 1 b) were ligated to this fragment and the ligation
product was digested with Nco I and Sal I before cloning in the vector pBS100.
Oligonucleotides were synthesized by the phosphoramidite method using DNA synthesiz-
ers (No. 380A; Applied Biosystems, Inc., Foster City, CA). DNA cloning and linker
ligations were carried out by standard techniques (15). The vector pBS100 contains ^-1
kb ofthe regulatory region ofthe Saccharomyces cerevisiae alcohol dehydrogenase 2 (ADH-
2) promoter (Cousens, L. S., J. R. Shuster, C. Gallegos, L. Ku, M. M . Stempien, M. S.
Urdea, R. Sanchez-Pescador, A. Taylor, and P. Tekamp-Olson, manuscriptsubmitted for
publication; and Shuster, J., unpublished data) and ^-200 by of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) promoter (16). This hybrid promoter, together with
the GAPDH transcriptional terminator, flanks a region of the human immunodeficiency
virus (HIV) envelope gene in pBS100 (Barr, P. J., K. S. Steimer, E. A. Sabin, et al.,
manuscript in preparation). Replacement of the HIV sequences with the P. vivax Nco-
1/Sal-1 fragment gave the plasmid pBS100/vivax-1 . The promoter-gene-terminator
expression cassette was excised from pBS100/vivax-1 as a Bam HI fragment and cloned
into Bam HI and phosphatase-treated pAB24. pAB24 (provided by Dr. A. J. Brake,
Chiron Corp.) is an autonomously replicating yeast plasmid containing pBR322 sequences
for amplification in Escherichia coli, and URA3 and LEU2 markers for selection of ura or
leu yeast auxotrophs in uracil- or leucine-deficient media. Yeast strain AB110 (16) was
transformed with the expression plasmid, designated pAB24/vivax-1 and leucine proto-
trophs selected and grown in minimal media lacking leucine and containing 8% glucose.
For induction and analysis ofvivax-1 CS protein, yeast cellswere diluted 1 :20 into medium
containing 1 % glucose and were grown for 36 h at 30'C. A second plasmid encoding
amino acids Ala 77 to Leu 335 was constructed using the Nco-1/Ban-1 fragment from
vivax-1 together with synthetic DNA encoding amino acids Glu 307 to Leu 335. The
resultingplasmids pBS 100/vivax-2 and pAB24/vivax-2 (not shown) were used as described
for vivax-1 for the production of the corresponding vivax-2 protein.
SyntheticPeptides.
￿
The 18-mer peptide (DGQPAGDRA)2 was synthesized as described
in (12). The tetradecapeptide CY(PKNPRGNKLKNP) was synthesized by Dr. D. H.
Schlesinger on 1 g of a benzhydrylamine resin (0.67 mEg/g, Beckman Instruments, Inc.,
Palo Alto, CA) with Boc-L-amino acids (Bachem, Torrance, CA) using a modified solid-
phase peptide synthesis (17, 18) on a Vega model 250c automated peptide synthesizer
controlled by an Apple 11 C computer. The following side chain protecting groups were
used: Cys, 4 methoxybenzyl; Tyr, 0-2,6-dichlorobenzyl; Lys, 2-chlorocarbobenzoxy; Asn
and Gin, nitrophenyl ester; Arg, tosyl; Glu, o-benzyl. The cysteine and tyrosine residues
are not part of the CS protein sequence and were added to facilitate radiolabeling and
coupling to carrier proteins. After completion of synthesis the peptide resin was treated
with anhydrous hydrogen fluoride (HF) (10 ml/g peptide resin) at 0°C for 60 min in the
presence of anisole as free radical scavenger to remove protecting groups and to cleave
the peptide from the resin. The crude peptide was extracted using alternate washes of
glacial acetic acid and water and then was lyophilized. The peptide was desalted and
purified on a 100 X 1 .9 cm column of Sephadex G-25 equilibrated with 1 N acetic acid.
The final tetradecapeptide product gave the following amino acid composition: Asp (2),
1 .77; Glu (2), 2.06; Pro (3), 3 .10, Cys (1 .0), 0.74; Leu (1), 1 .06; Tyr (1), 0.84; Lys (3),
2 .85 ; Arg (1), 1 .02.
Radioimmunoassay (RIA).
￿
The purified engineered CS polypeptide was radiolabeled
with ' 251 to a sp act of 2 X 106 cpm/kg protein using Iodogen. A standard curve relating
the dose of antigen with the specific counts per minute obtained in the RIA was included
in every assay; 30 ul of mixtures containing a constant amount of radiolabeled antigen
and increasing amounts ofpurified cold antigen were delivered to the bottom of wells of
microtiter plates precoated with a mAb (2F2) against the repeats ofCS protein ofP. vivax
(19) and then were saturated with BSA. After incubation at room temperature, the wells
were washed and the radioactivity was counted in a gamma counter. As a negative control,
30 ,ul of the same mixtures were delivered to wells coated with BSA alone, and the RIA
was performed as above. The counts per minute observed in the controls were subtractedBARR ET AL .
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from the corresponding experimental values. The cold antigen inhibited the binding of
the hot antigen to theimmobilized 2F2antibody in adose-dependent manner . All dilutions
were performed in a PBS containing 1% BSA and 0.1% sodium azide . To determine the
antigen concentration in fractions obtained during the purification procedure, duplicate
samples were mixed with the labeled-purified antigen, and the RIA was performed as
above . The concentrations of cold antigen were calculated by referring the mean of the
results of the duplicate measurements to the standard curve. The counts per minute in
the duplicates did not differ by >10% from the mean values . The RIA detected antigen
at concentrations as low as 5 ng/ml .
Immunoradiometric Assay(IRMA).
￿
Wells of microtiter plates were coated with purified
engineered polypeptide or with synthetic peptides at a concentration of 10 Ag/ml in PBS.
The wells were saturated with 1% BSA and incubated with 30 Al of increasing dilutions
in PBS-1% BSA of the immune sera . After incubation for 1 h at room temperature the
wells were washed and reincubated with 5-10 ng of radiolabeled, affinity-purified goat
antibodies to mouse Igs (2 X 10' cpm/log protein) . After a second incubation of 1 h at
room temperature, the wells were washed and counted in a gamma counter .
NH2-Terminal Sequencing Analysis .
￿
This was performed by Dr. D. H. Schlesinger in a
gas-phase sequencer(No . 470A; Applied Biosystems, Inc.) usingapolybrene-treated glass
filter that had been conditioned by several cycles of the Edman degradation .
Immunization ofMice .
￿
The purified antigen was dissolved in water and adsorbed onto
aluminum hydroxide . 10 mice were injected intramuscularly with 0.7 mg of the adjuvant
coated with the antigen in a volume of 100,ul . Booster injections were given 3 and 6 wk
afterwards . Serum samples were obtained 10 days after each antigen injection .
In Vitro Assayfor Sporozoite Neutralization .
￿
This was performed as described in (9) .
Results and Discussion
For expression of the P. vivax CS antigen in yeast, we constructed plasmids
containing DNA coding for 234 amino acids (Ala 77 to Pro 310) of the P. vivax
CS protein (Fig . 1 a). If the 39 amino acids representing the hydrophobic leader
and presumed anchor sequences are excluded, this represents ^-70% of the
amino acids encoded by the P. vivax CS gene, and most likely an even larger
proportion of the amino acids found in the mature, membrane form of the CS
protein . The DNA encoded all amino acids from the repeat domain (19 tandem
sequences DRAAGQPAG), 15 amino acids preceding the repeats, and 48 amino
acids flanking the repeats at their COOH-terminal end .
Although the NH2-terminal amino acid of the genuine processed membrane
form of the CS protein is unknown, immunological evidence suggests that it
comprises several amino acids upstream of the repeat domain (20) . We have
selected Ala 77 as the NH2-terminal of the expressed antigen because, immedi-
ately preceding it, the CS protein gene codes for a cluster of basic residues that
could be the site for proteolytic processing of the intracellular precursor and
generation of the membrane form . The chosen DNA fragment included the
codons for the highly conserved sequence KLKQP found in all CS proteins
sequenced to date (5, 21) .
For expression in yeast we chose to use a hybrid promoter based on the strong
yeast glyceraldehyde-3-phosphate dehydrogenase promoter (16) and the glucose
regulatable alcohol dehydrogenase-2 (ADH-2)promoter . Fusion of thispromoter
to heterologous genes allows the growth of yeast cultures to high density using
glucose as a carbon source . Depletion of glucose in the medium during fermen-
tative growth gives concomitant induction of expression of the heterologous
protein. Translation frames encoding P. vivax CS antigens were fused to this1164
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FIGURE 2 .
￿
Extracts from pelleted yeast from 20 liters of yeast culture were prepared in a
bead beater, diluting the yeast in an equalvolume of 0.1 M sodium phosphate buffer, pH 7.3,
0.1% Triton-X, 1 mM EDTA, 1 mM PMSF, and 1 ug per ml of pepstatin. The extract (370
ml) was added to 200 ml of boiling water containing 1 ml of PMSF and 1 Ag of leupeptin .
The mixture was brought to 100°C and kept for 10 min with constant stirring at this
temperature . The mixture was cooled to 0 °C and centrifuged at 18,000 rpm in a Ultracen-
trifuge Rotor TI-19 (Beckman Instruments, Inc.) for 15 min . The supernatant was then
lyophilized .
The dry material was dissolved in 120 ml of water, centrifuged to remove a small residual
amount of insoluble material, dialyzed extensively against distilled water for 48 h, and
lyophilized again . Thepowder was dissolved in 3mM sodium potassium phosphate buffer, pH
7.5, and the conductivity was adjusted with water to 0.58 mS . The solution was centrifuged
to remove insoluble materials and subjected to anion-exchange chromatography in a DEAE-
Sephacel (Pharmacia Fine Chemicals, Piscataway, NJ)column (5 cm x 24 cm) equilibrated in
the same buffer . The flow rate was adjusted to 100 ml/h and 21 ml per tube were collected .
The column was then washed with 500 ml of the same buffer. The elution continued with a
buffer formed in a linear gradient in which 1,500 ml of the initial buffer were mixed with
1,500 ml of the same buffer containing 0.75 M NaCL
The positive fractions in the RIA (10) eluted between fraction nos. 50-80, corresponding
to a relatively small optical density peak, at conductivities between 2 and 10 mS . Thepooled
fractions 50-80 were lyophilized, redissolved in 60 ml of0.3 M NaCl, and dialyzed against
0.3M NaCI at room temperature for several hours . The dialyzate was centrifuged to remove
a small amount of insoluble material and one-third, i.e . 20 ml, was subjected to molecular-
sieve chromatography on Sephadex G-200 (Pharmacia Fine Chemicals) equilibrated with
sodium chloride 0.3 M. The Sephadex was superfine and the column was 5 cm in diameter
and 100 cm long . Samples of 21 ml per tube were collected from the column. The CS
polypeptide eluted in a sharp symmetrical peak with an M, of 50,000 . However, CS antigen
with higher and lower molecular weight in smaller amounts was found in several tubes
precedingand following this peak . The contents of tubes in the main peak of antigen were
pooled, dialyzed extensively against distilled water, and lyophilized . A total amount of 89 mg
of CS antigen wasrecovered.
promoter using synthetic oligonucleotide adapters . Incorporation of these con-
structions into high copy number, autonomously replicating yeast plasmids and
transformation of yeast cells, generated strains that could express high levels of
CS antigens upon induction .
The isolation of the CS polypeptide antigen from the yeast extracts trans-
formed with this plasmid was monitored by a solid-phase competitive RIA. The
first steps of purification consisted of heating the extracts at 100'C for 10 min
and removing the large amounts of denatured insoluble materials by centrifuga-
tion (see legend of Fig . 2 for details) . This approach was based on our prior
observations that the antigenic reactivity of the repetitive epitopes ofCS proteinsBARR ET AL .
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FIGURE 3 . (Top) SDS-PAGE analysis
under reducing conditions in 7.5% acryl-
amide gels of(1) total yeast extracts, (2)
molecular weight markers, (3) purified
CS protein (2 mg/ml) obtained after an-
ion-exchange and molecular sieve chro-
matography, (4) supernatant obtained
after heating the extracts at 100°C for
10 min. (Bottom) Isoelectric focusing un-
der denaturing conditions of the puri-
fied CS antigen (2 mg/ml) . The gels
were dried and stained with Coomassie
blue .
was unaltered by this treatment (22). The supernatant of the boiled yeast extract
was subjected to ion-exchange chromatography and eluted with a salt gradient .
The positive fractions, found in a symmetrical optical density peak with conduc-
tivities between 2 and 10 mS (Fig . 2), were pooled, concentrated, and subjected
to molecular-sieve chromatography . Most of the CS polypeptide eluted in a sharp
peak with an apparent Mr between 40,000 and 60,000, but reactive molecules
with higher and lower M, were found in tubes preceding and succeeding the
major peak of inhibitory activity in the RIA .
All of the engineered CS polypeptide was recovered in the yeast extract
supernatant obtained after boiling, which was devoid of most yeast proteins (Fig .
3) . The few remaining contaminants as well as large amounts of nucleic acids
were removed in the subsequent steps of purification . In three separate runs, the
yields of purified antigen were between 15 and 25 mg per liter of culture . The
purified CS antigen was soluble in water at concentrations >50 mg/ml . Its
extinction coefficient at 280 nm at a concentration of 1 mg/ml (determined by
Kjeldahl nitrogen analysis) was 0.2 . The SDS-PAGE analysis revealed a doublet
with 43,000-45,000Mr . This is a much higherMr than that expected from the
calculated molecular weight of 22 .7 kD . However, several CS proteins or engi-
neered repeat domains migrate abnormally in SDS-PAGE (23, 24), probably due
to the low proportion of hydrophobic residues . Indeed, by isoelectric focusing
under denaturing conditions, a single band was detected with a pl of 4.3 . The
purity of the preparation was also assessed by immunoprecipitation ofa radiola-
beled sample by the mAb 2F2 and capture of the immune complexes with
Sepharose-protein A. In several experiments, 80 ± 5% of the labeled protein
was specifically recognized by the antibody .
A sample of the protein was subjected to six steps of NH2-terminal sequencing
analysis and the major peaks of amino acids were AEPRNP . This sequence1166
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FIGURE 4. Antibody response of Swiss-Webster mice to the
yeast-engineered P. vivax CS polypeptide. Antibodies were de-
tected by solid phase IRMA. Assays were run in duplicate and
the averages did not differ by more than 15% from the experi-
mental values. Shown are antibody titrations against the engi-
neered CS protein (top), the Pro79-Pro87 peptide (middle) and
the repeat peptide (bottom). Symbols represent pooled sera from
bleeding obtained after the first antigen injection (A), first
booster (A), and second booster ([I), and normal mouse serum
(O).
corresponds to that ofthe predicted NH2-terminal of the expressed polypeptide,
except that the engineered NH2-terminal methionine is absent, probably due to
the presence in the yeast extracts of a specific aminopeptidase. This is not
unprecedented, since the HIV reverse transcriptase has been shown to be thus
processed (25). Also, recombinant human superoxide dismutase (hSOD), a pro-
tein that is normally acetylated in human cells, is appropriately modified by
methionine removal and acetylation in yeast (26).
Three groups of 10 female Swiss-Webster 8-12-wk-old mice were injected
intramuscularly three times at 3 wk intervals with 50, 100, or 250 Ag of the
purified recombinant protein adsorbed onto aluminum hydroxide. Preceding
each booster, and 10 days after each booster injection, the mice were bled and
the sera were assayed for the presence of antibodies using a solid-phase IRMA
assay.
3 wkafterthe initial injections ofantigen, allmicealready had serum antibodies
against the recombinant protein. After the second booster, reciprocal titers were
?20,000 (Fig. 4). We found no significant difference in the geometrical means
of serum titers between the groups of mice receiving increasing antigen doses.
To define the domains ofthe recombinant antigen recognized by the antibodies,Oiif rgn
BARR ET AL .
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TABLE I
Neutralization ofthe Infectivity ofP. vivax Sporozoites* In Vitro
* 5.10 5 ONG strain P . vivax sporozoites added to each culture.
EEF, number of intracellular (exoerythrocytic) forms. In the case of
preimmune sera, the numbers represent the mean t SD of the EEF seen
in four coverslips incubated with a 1:20 dilution of serum ; the numbers
that follow are the numbers of EEF in two coverslips incubated with
various dilutions of immune sera .
4Calculated as 100 - [(mean experimental values/mean of controls) X
1001 .
we performed IRMAs using as antigen two synthetic peptides, one representing
the repeat domain (DGQPAGDRA)2 and the other representing amino acids Pro
79 through Pro 87 of the protein encoded by the CS gene . All sera reacted with
the two peptides, but the titers were significantly higher against the repeat
peptide .
In other experiments we found that ^-50% of the reactivity of the pooled sera
with the engineered protein was inhibited by the synthetic repeat peptide . We
first incubated samples of a 1:3,000 dilution of the pooled serum from mice
(obtained after the second booster injection) with increasing concentrations of
the 18-amino-acid repeat peptide . As acontrol, samples ofserumwere incubated
with the same concentration of another 24-mer peptide with a different and
unrelated sequence of amino acids representing the repeat peptide from the
Plasmodium knowlesiCS protein (23) . After a 1-h incubation at room temperature,
30 ul of the mixtures (or of controls containing no peptides) were added to wells
of plates precoated with the engineered CS polypeptide . After 1 h of incubation
the wells were washed, incubated for 1 h with radiolabeled goat anti-mouse Ig,
washed again, and counted. The results demonstrated that the repeat peptide
(but not the control peptide) inhibited in a dose-dependent fashion the reaction
between the antibodies and the engineered CS protein . A maximum of 50%
inhibition was obtained with a 10-s M concentration of the synthetic peptide
(not shown) .
A pool of sera from mice receiving the lowest dose of antigen and obtained
10 days after the second booster injection was assayed both for reactivity with P.
vivax sporozoites by indirect immunofluorescence (IFA) of glutaraldehyde-fixed
parasites and for the ability to neutralize the parasite infectivity in vitro . The
pooled sera reacted strongly with P. vivax sporozoites, as shown by IFA (recip-
rocal titers of 1,000) and effectively blocked invasion of a hepatoma cell line in
vitro (Table I) . Significant inhibition of invasion was detected at dilutions of
1 :5,000 . As mentioned above, the sera also contained antibodies to the sequence
serum Dilution EEF$ Inhibition4
Preimmune 1:20 122 t 12
Immune 1:50 12,10 91.0
1 :250 12,11 90.6
1 :1,000 33,27 75.4
1 :5,000 74,68 41.81168
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ofamino acids Pro 79 to Pro 87 found upstream and immediately flanking the
repeats. Although this sequence includes five amino acids that are conserved in
all CS proteins sequenced to date, the antibodies did not react with glutaralde-
hyde-fixed sporozoites from otherrodent or human malaria parasites. Additional
experiments are necessary to determine the fine specificity of these antibodies
and to study their possible role in the serum-mediated neutralization of the P.
vivax sporozoites.
We show here that large amounts of a homogeneous P. vivax CS antigen can
be isolated from the engineered yeast cultures. This high yield, the simplicity of
the purification procedure, the ease with which yeast grows in large volumes of
inexpensive media, andthe convenient induction ofexpression ofthepolypeptide
at the fermentation level, suggest that this system is amenable to large-scale
production of a malaria vaccine. Yeast expression systems have demonstrated
applicability to the production of heterologous proteins with clinical uses (16,
27, 28). Indeed, yeast-derived recombinant hepatitis B vaccines have been shown
to be a safe and effective vaccine in humans (29). The convenient construction
scheme described here can be used toexpress other portions ofthe CS molecule.
For example, we also produced large quantities of a protein (vivax-2) encom-
passing Ala 77 to Leu 335 ofthe CS polypeptide sequence in an attempt to raise
antibodies to conserved COOH-terminal regions ofthe molecule.
Ideally, a sporozoite malaria vaccine should contain both B and T cell CS
protein epitopes to stimulate the production of neutralizing antibodies and also
of CS-specific memory Th cells. The expansion of the population of T cells
would insure that a secondary immune response would be triggered upon
encounter with the invading sporozoites, and that IFN-y would be produced to
inhibit the development of the remaining exoerythrocytic, intrahepatic forms
(30, 31). In mice, however, T cell recognition of the repeats ofthe P.falciparum
CS protein is severely restricted genetically. Among 14 inbred strains, with 9
different H-2 haplotypes, only mice bearing H-26 were responsive (32-34). This
finding raises the possibility that a vaccine containing only repeats may not be
recognized by the T cells ofall humans. Therefore, at least until the structures
representing the Tcell epitopes ofCS protein are known and can be engineered
into subunit vaccines, these should contain as wide,' and as faithful a representa-
tion of the native CS molecules as possible (35).
The yeast antigen here described contains large segments ofthe CS protein of
P. vivax in addition to the repeat domain, and no other covalently bound
extraneous materials. Mice produced high titers ofantibodies against the repeats
and another highly conserved region of the CS protein of P. vivax, after
administration ofthe protein adsorbed onto alum, an adjuvant that can be used
in humans. The antibodies recognized the authentic CS protein and at high
dilutions they inhibited the invasion of hepatocytes by P. vivax sporozoites in
vitro. Moreover, T-dependent secondary antibody responses in vitro were ob-
tained by incubation of lymphoid cells from these mice with P. vivax sporozoite
extracts (Nardin, manuscript in preparation). It appears, therefore, that the yeast
antigen has potential advantages over other types of subunit vaccines consisting
of recombinant fusion proteins, or of synthetic peptides coupled to nonrelevant
carrier molecules. It remains to be determined whether this type ofvaccine willstimulate the production of antibodies and of CS protein-specific T cells in a
human population .
Summary
DNA coding for 234 amino acids of the circumsporozoite (CS) protein of
Plasmodium vivax was incorporated into yeast expression vectors . The DNA
encoded all the repeat domain and codons for a highly conserved sequence,
KLKQP, found in CS proteins from all malaria parasites . Yeast cells transformed
with these autonomously replicating plasmids expressed, upon induction, high
levels of the CS polypeptide . The malaria antigen was purified in good yields
from yeast extracts and was injected into mice using alum as adjuvant . The
antibodies recognized the authentic CS protein, and at high dilutions, they
inhibited the invasion of hepatocytes by sporozoites in vitro .
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